My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

48.35 -0.52 (-1.06%)

Streaming Delayed Price Updated: 12:16 PM EST, Nov 19, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

34 35 Next >

Down Nearly 20%: Should You Buy the Dip on Eli Lilly? ↗

May 08, 2025

Via The Motley Fool

The 'Double Whammy' That Sent Sarepta Stock To An Eight-Year Low ↗

May 07, 2025

Sarepta stock plummeted Wednesday on a "double whammy" that includes its trimmed 2025 sales outlook and a critical FDA appointment.

Via Investor's Business Daily

Topics Death

FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight ↗

May 06, 2025

FDA to increase surprise inspections at foreign facilities as U.S. companies pour billions into domestic drug and device manufacturing.

Via Benzinga

3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.

April 28, 2025

See these three top-10 stocks in the pharmaceutical industry that are pledging investment in the United States totalling over $100 billion.

Via MarketBeat

Topics Artificial Intelligence Economy Government

New England Journal of Medicine Publishes Phase III Data Showing Single-dose Xofluza Significantly Reduces Influenza Virus Transmission

April 25, 2025

From Genentech

Via Business Wire

Pharma Giant Roche Tops First-Quarter Views; Sanofi's Sales Come In Mixed ↗

April 24, 2025

Roche rode its pharmaceuticals growth to a sales beat, while Sanofi's report was more complicated.

Via Investor's Business Daily

Topics Earnings Government

Roche Plans $50 Billion US Investment Over 5 Years With 12,000 New Jobs ↗

April 22, 2025

Roche to invest $50 billion in U.S. over five years, adding 12,000+ jobs and expanding manufacturing, R&D, and export capacity across eight states.

Via Benzinga

Roche's $50 Billion US Investment Commitment Includes New Facilities, 12,000 Jobs, Expanded R&D Hubs As Drug Tariffs Loom ↗

April 22, 2025

Roche plans $50B investment in U.S. for manufacturing & research, as potential drug tariffs loom. Move to create 12,000 jobs & increase exports

Via Benzinga

Topics World Trade

What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday? ↗

April 14, 2025

Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid obesity drug competition.

Via Benzinga

Omeros' New Leukemia Drug Team Ignites Hope For Cancer Fight ↗

April 11, 2025

Omeros forms oncology committee to guide development of its AML therapy, which showed strong efficacy and safety in preclinical studies targeting leukemia cells.

Via Benzinga

Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success ↗

April 10, 2025

Tempest Therapeutics hires MTS Health to explore M&A and partnerships after Roche shows limited interest in its liver cancer program.

Via Benzinga

Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline ↗

April 09, 2025

Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs.

Via Benzinga

Topics Government Supply Chain World Trade

Why Roche Holding, Eli Lilly, and AstraZeneca Stocks Dropped Today ↗

April 09, 2025

Might the tariff risk for pharmaceutical stocks be less than you think?

Via The Motley Fool

Topics Government World Trade

Roche To Start Phase 3 Study For Alzheimer's Prospect This Year After New Data From Phase 2 ↗

April 04, 2025

Roche's trontinemab data showed dose-dependent amyloid reduction in Alzheimer's patients, while its Elecsys pTau181 test aims for European launch in 2025

Via Benzinga

Trump Tariffs Spare Drugmakers But Threaten Diabetes Device Industry ↗

April 04, 2025

Trump's 10% global tariff spares pharmaceuticals but impacts medical devices, with diabetes device makers facing the greatest strain. Large biopharma firms remain protected, while medtech companies...

Via Benzinga

Topics Government World Trade

Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death ↗

April 03, 2025

Sarepta and Roche paused Elevidys trials in the EU after a patient death. Analysts warn of potential sales declines as safety concerns impact market outlook.

Via Benzinga

Genentech and Roche Present Novel Therapeutic and Diagnostic Advancements in Alzheimer’s at AD/PD 2025

April 03, 2025

From Genentech

Via Business Wire

Why Is Pharma Giant Roche Stock Trading Lower On Wednesday? ↗

April 02, 2025

Roche's MUSETTE trial found no additional benefit of high-dose Ocrevus over the 600 mg IV dose, reaffirming its efficacy and safety for relapsing multiple sclerosis.

Via Benzinga

IBD 50 Stock TG Therapeutics Rallies On A Setback For Chief Rival Roche ↗

April 02, 2025

The companies both have drugs that treat relapsing forms of multiple sclerosis.

Via Investor's Business Daily

Genentech Provides Update on Phase III Ocrevus High Dose Study in People With Relapsing Multiple Sclerosis

April 02, 2025

From Genentech

Via Business Wire

Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed ↗

March 21, 2025

UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness.

Via Benzinga

Novartis New Data From Single-Dose Gene Therapy Shows Meaningful Efficacy, Safety In Patients With Spinal Muscular Atrophy ↗

March 19, 2025

Novartis' OAV101 IT gene therapy showed positive results in Phase 3 trials for SMA, with data supporting its potential as a treatment option.

Via Benzinga

The Best Vanguard ETF to Invest $1,000 in Right Now ↗

March 18, 2025

Via The Motley Fool

Topics ETFs

Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped ↗

March 12, 2025

Ignore the noise in GLP-1 stocks. Find the best value instead.

Via The Motley Fool

Roche Inks 'The Largest Obesity Deal To Date' With Zealand Pharma At $5.3 Billion ↗

March 12, 2025

The company is looking to test a combination of the drug it acquired from Carmot Therapeutics and a amylin-based drug.

Via Investor's Business Daily

Roche Further Boosts Obesity Pipeline With Zealand Pharma Deal Worth $5.3 Billion For Weight Loss Drugs ↗

March 12, 2025

Roche partners with Zealand Pharma on obesity drug petrelintide, with a $5.3B deal including milestone payments and global commercialization rights.

Via Benzinga

FDA Accepts Supplemental Biologics License Application for Genentech’s Gazyva for the Treatment of Lupus Nephritis

March 05, 2025

From Genentech

Via Business Wire

FDA Approves Genentech’s TNKase® in Acute Ischemic Stroke in Adults

March 03, 2025

From Genentech

Via Business Wire

Roche Touts Food Allergy Drug As Superior Than Oral Immunotherapy ↗

March 03, 2025

Roche's Xolair outperformed oral immunotherapy in a Phase 3 trial for food allergies, showing better tolerance and fewer adverse events.

Via Benzinga

Phase III Study Shows Xolair May Be More Effective With Fewer Side Effects Than Oral Immunotherapy for the Treatment of Food Allergies

March 02, 2025

From Genentech

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

34 35 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.